109 related articles for article (PubMed ID: 15007871)
1. [Evaluation of ketoride antibiotics, telithromycin in treatment of respiratory tract infections (discussion)].
Kohno S; Watanabe A; Aoki N; Niki Y
Jpn J Antibiot; 2003 Dec; 56(6):531-45. PubMed ID: 15007871
[No Abstract] [Full Text] [Related]
2. Clinical efficacy of ketolides in the treatment of respiratory tract infections.
Reinert RR
J Antimicrob Chemother; 2004 Jun; 53(6):918-27. PubMed ID: 15117934
[TBL] [Abstract][Full Text] [Related]
3. Telithromycin (Ketek) for respiratory infections.
Med Lett Drugs Ther; 2004 Aug; 46(1189):66-8. PubMed ID: 15314586
[No Abstract] [Full Text] [Related]
4. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
Carter PL
Postgrad Med; 2002 Sep; 112(3 Suppl):18-25. PubMed ID: 19667591
[TBL] [Abstract][Full Text] [Related]
5. Telithromycin.
Spiers KM; Zervos MJ
Expert Rev Anti Infect Ther; 2004 Oct; 2(5):685-93. PubMed ID: 15482232
[TBL] [Abstract][Full Text] [Related]
6. Telithromycin (Ketek) for community-acquired respiratory tract infections.
Wimett L; Laustsen G
Nurse Pract; 2004 Sep; 29(9):56-60. PubMed ID: 15359148
[No Abstract] [Full Text] [Related]
7. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M
J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000).
Kohno S; Hoban D;
J Chemother; 2003 Aug; 15(4):335-41. PubMed ID: 12962361
[TBL] [Abstract][Full Text] [Related]
9. [Telithromycin].
Benes J
Klin Mikrobiol Infekc Lek; 2004 Feb; 10(1):16-21. PubMed ID: 15100978
[TBL] [Abstract][Full Text] [Related]
10. [Acute respiratory tract infection in chronically ill patients. germ spectrum different than in healthy persons].
MMW Fortschr Med; 2003 Dec; 145(49):61. PubMed ID: 14964003
[No Abstract] [Full Text] [Related]
11. Comparative activity of telithromycin against typical community-acquired respiratory pathogens.
Buxbaum A; Forsthuber S; Graninger W; Georgopoulos A
J Antimicrob Chemother; 2003 Sep; 52(3):371-4. PubMed ID: 12888585
[TBL] [Abstract][Full Text] [Related]
12. [Telithromycin: a new therapeutic option for community-acquired respiratory infection].
Muñoz MJ; Azanza JR; Escolar M; Macaya A; Gil FJ
Rev Med Univ Navarra; 2002; 46(3):37-44. PubMed ID: 12685116
[No Abstract] [Full Text] [Related]
13. [Importance in respiratory tract infections. Ketolides: clinical aspects].
Lorenz J; Steiert P
Pharm Unserer Zeit; 2004; 33(1):42-6. PubMed ID: 14968712
[No Abstract] [Full Text] [Related]
14. Clinical management of respiratory tract infections in the community: experience with telithromycin.
Quintiliani R
Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
[TBL] [Abstract][Full Text] [Related]
15. [Multicenter study in southern South America of the in vitro activity of telithromycin in strains with defined resistance phenotypes isolated from community-acquired respiratory infections].
Casellas JM; Visser M; Mac Dougall N; Coco B; Tomé G; Gliosca L;
Rev Esp Quimioter; 2001 Sep; 14(3):269-74. PubMed ID: 11753448
[TBL] [Abstract][Full Text] [Related]
16. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
Felmingham D
J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
[TBL] [Abstract][Full Text] [Related]
17. Telithromycin.
Raja A; Lebbos J; Kirkpatrick P
Nat Rev Drug Discov; 2004 Sep; 3(9):733-4. PubMed ID: 15368658
[No Abstract] [Full Text] [Related]
18. Will resistance to ketolides develop in Streptococcus pneumoniae?
Leclercq R
J Infect; 2002 Feb; 44 Suppl A():11-6. PubMed ID: 12150490
[TBL] [Abstract][Full Text] [Related]
19. Tissue kinetics of telithromycin, the first ketolide antibacterial.
Muller-Serieys C; Andrews J; Vacheron F; Cantalloube C
J Antimicrob Chemother; 2004 Feb; 53(2):149-57. PubMed ID: 14729764
[TBL] [Abstract][Full Text] [Related]
20. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
Lorenz J
Int J Clin Pract; 2003; 57(6):519-29. PubMed ID: 12918892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
